

Marcia S Brose

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1003378/publications.pdf>

Version: 2024-02-01

41
papers

6,017
citations

331670

21
h-index

315739

38
g-index

42
all docs

42
docs citations

42
times ranked

6793
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 621-630.	27.0	1,526
2	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2014, 384, 319-328.	13.7	1,295
3	BRAF and RAS mutations in human lung cancer and melanoma. <i>Cancer Research</i> , 2002, 62, 6997-7000.	0.9	848
4	Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1365-1372.	6.3	611
5	Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2981-2992.	1.6	364
6	Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2016, 17, 1272-1282.	10.7	290
7	Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2692-2699.	1.6	144
8	Management of Sorafenib-Related Adverse Events: A Clinician's Perspective. <i>Seminars in Oncology</i> , 2014, 41, S1-S16.	2.2	111
9	Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2015, 33, 786-809.	1.6	102
10	Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. <i>BMC Cancer</i> , 2011, 11, 349.	2.6	84
11	Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). <i>Cancer</i> , 2018, 124, 2365-2372.	4.1	77
12	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2359-2366.	1.6	64
13	Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 631-643.	3.7	55
14	Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1137-1147.	2.4	54
15	Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 295-305.	4.7	43
16	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. <i>Head and Neck</i> , 2022, 44, 1277-1300.	2.0	41
17	Management of treatment-related toxicities in advanced medullary thyroid cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 64-73.	7.7	38
18	Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6018-6018.	1.6	34

#	ARTICLE	IF	CITATIONS
19	A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 776-787.	3.6	33
20	A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6016-6016.	1.6	29
21	The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA2501-LBA2501.	1.6	27
22	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with ¹³¹ I-refractory differentiated thyroid cancer (SELECT).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA6008-LBA6008.	1.6	23
23	STK11 Mutation Identified in Thyroid Carcinoma. <i>Endocrine Pathology</i> , 2016, 27, 65-69.	9.0	17
24	Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. <i>Thyroid</i> , 2019, 29, 1820-1827.	4.5	15
25	Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7370-7380.	7.0	12
26	Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 748.	2.2	11
27	A phase 1b/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 16-16.	1.6	10
28	Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 7-12.	0.3	9
29	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 312-317.	4.1	8
30	Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5596-5596.	1.6	8
31	A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8595-TPS8595.	1.6	7
32	Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer. <i>Clinical and Translational Science</i> , 2019, 12, 459-469.	3.1	6
33	Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6061-6061.	1.6	6
34	In Search of a Real "Targeted" Therapy for Thyroid Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1827-1829.	7.0	5
35	Sorafenib for patients with differentiated thyroid cancer " Authors' reply. <i>Lancet, The</i> , 2015, 385, 228-229.	13.7	5
36	Biomarkers of prognosis in patients with differentiated thyroid cancer: Results from the DECISION trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6059-6059.	1.6	2

#	ARTICLE	IF	CITATIONS
37	RNAseq analysis of the sorafenib phase III DECISION trial in differentiated thyroid cancer (DTC): Correlation with clinical outcome.. Journal of Clinical Oncology, 2017, 35, 6083-6083.	1.6	1
38	Understanding the Mechanism of Late Sorafenib Failure in Metastatic Thyroid Cancer. Laryngoscope, 2009, 119, S237.	2.0	0
39	Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer – Authors' response. Lancet Oncology, The, 2016, 17, e469.	10.7	0
40	Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study. Journal of Clinical Oncology, 2022, , JCO2200556.	1.6	0
41	Clinical application of precision medicine among oncologists: A case study in <i>RET</i> -targeted therapy.. Journal of Clinical Oncology, 2022, 40, e18705-e18705.	1.6	0